Waxman reiterates scientific review request

Incoming Committee on Government Reform Chair Rep. Henry Waxman (D-CA) reiterated his request that the FDA conduct a thorough scientific review of phenylephrine's effectiveness at 10 mg as used in reformulated OTC decongestants, citing a DTC ad for Schering-Plough's Claritin-D indicating the company will not reformulate it.

December 1, 2006

5:00 am

Incoming Committee on Government Reform Chair Rep. Henry Waxman (D-CA) reiterated his request that the FDA conduct a thorough scientific review of phenylephrine’s effectiveness at 10 mg as used in reformulated OTC decongestants, citing a DTC ad for Schering-Plough’s Claritin-D indicating the company will not reformulate it.

From the December 01, 2006 Issue of MM+M - Medical Marketing and Media

From Our Partners

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.